Welcome to our dedicated page for Picard Medical SEC filings (Ticker: PMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Picard Medical, Inc. (PMI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Picard Medical is a Delaware corporation listed on the NYSE American, and its filings describe a business conducted through SynCardia Systems, LLC, a medical technology company that manufactures and sells the SynCardia Total Artificial Heart (STAH) for patients with advanced heart failure.
Through documents such as Form S-1 registration statements and Form 8-K current reports, investors can review detailed information about Picard Medical’s operations, financing arrangements, and risk factors. The S-1 filing explains that SynCardia’s platform includes the SynCardia 50cc and 70cc total artificial hearts, external drivers, ancillary hardware, and associated surgeon and center training. It also notes that the company’s customers are major medical centers operating heart transplant and mechanical circulatory support programs and that SynCardia operates an ISO 13485–certified quality management system.
Form 8-K filings for Picard Medical include disclosures on material definitive agreements, such as senior secured notes and warrant financings, bridge financing arrangements, and related security agreements. Additional 8-Ks furnish press releases and presentation materials related to clinical and technical updates on the next-generation, fully implantable Emperor Total Artificial Heart, as well as corporate events like conference presentations and exchange bell-ringing ceremonies.
On this page, users can follow real-time updates from EDGAR and use AI-powered summaries to understand the key points in lengthy filings. Forms such as the S-1, 8-K, and any future 10-K annual reports, 10-Q quarterly reports, or proxy statements can provide insight into Picard Medical’s capital structure, governance, risk profile, and the progress of its SynCardia and Emperor total artificial heart platforms. Insider transaction reports on Form 4, when available, can also be reviewed to see changes in beneficial ownership by company insiders.
Picard Medical, Inc., parent of SynCardia Systems, announced that Vice President of Clinical Affairs Dr. Andre Simon will deliver three presentations at the Technology and Heart Failure Therapeutics 2026 conference in Boston from March 2 to March 4, 2026.
The talks will cover new in vitro and in vivo data for the fully implantable Emperor electromechanical total artificial heart, perspectives on the future of total artificial heart therapy, and updated clinical outcomes with the SynCardia Total Artificial Heart that extend beyond survival to organ recovery, functional improvement, and preservation of transplant eligibility.
Picard Medical, Inc., parent of SynCardia Systems, announced it will participate in the inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics 2026 conference in Boston on March 1, 2026. The session focuses on real-world use of the SynCardia Total Artificial Heart in advanced heart failure.
Senior Clinical Specialists Lauren Wallace and Skyler Peffly will lead small-group, case-based training using the Companion 2 Driver, Freedom Portable Driver, and the SynCardia Total Artificial Heart. SynCardia’s technology has been implanted in more than 2,100 patients across 27 countries and is described as the only commercially available total artificial heart in the United States and Canada.
Picard Medical, Inc. is asking shareholders at a virtual Special Meeting on
As of
Picard Medical, Inc. is asking stockholders at a special virtual meeting on March 10, 2026 to approve an amendment to its Certificate of Incorporation to increase authorized capital stock from 180,000,000 to 330,000,000 shares, including an increase in authorized common stock from 150,000,000 to 300,000,000 shares. As of February 6, 2026, 73,701,176 shares of common stock were outstanding, with additional shares reserved for an equity incentive plan, warrants and senior secured notes. The board says the increase is intended to provide flexibility to meet existing share issuance obligations and to support future financing and strategic transactions, while noting potential dilution and anti-takeover effects. The board unanimously recommends voting in favor of the proposal.
Picard Medical, Inc. received a large shareholder disclosure from Hudson Bay Capital Management LP and Sander Gerber. They report beneficial ownership of 7,009,346 shares of common stock, all issuable upon exercise of warrants, representing 8.68% of the common stock.
The percentage is based on 73,701,176 shares outstanding as of November 10, 2025, as stated in Picard Medical’s Form 10-Q, and assumes exercise of the warrants held by HT Investments MA LLC. The stake is reported on a passive basis and certified as acquired and held in the ordinary course of business, not to change or influence control of the company.
Picard Medical, Inc. is asking stockholders to approve an amendment to its Certificate of Incorporation to increase authorized capital stock from 180,000,000 to 330,000,000 shares, including an increase in authorized common stock from 150,000,000 to 300,000,000 shares.
As of February 6, 2026, the company had 73,701,176 shares of common stock outstanding and a total of 109,402,110 shares issued or reserved, leaving 40,597,890 common shares unreserved and available. The board says more authorized shares are needed to satisfy existing obligations tied to notes and warrants and to support future capital-raising and strategic transactions.
The proxy explains that additional shares could dilute existing holders and may have anti-takeover effects, though the board states it is not aware of any takeover attempt. The board unanimously recommends voting “FOR” the increase at the virtual special meeting on March 10, 2026.
Picard Medical, Inc. has registered up to 17,000,000 shares of common stock for resale by HT Investments MA LLC and High Trail Special Situations LLC. These shares include 7,009,346 shares issuable upon exercise of warrants and 9,990,654 shares issuable upon conversion, redemption, amortization, make‑whole or other share settlement of senior secured notes due December 24, 2028.
The company is not selling shares in this prospectus and will not receive proceeds from resales by the selling stockholders, though it may receive cash if the warrants, which have an initial exercise price of $2.675 per share, are exercised. Shares outstanding would rise from 73,701,176 to 90,701,176 if all 17,000,000 shares are issued, which would dilute existing holders.
The notes are senior secured obligations backed by substantially all Picard Medical’s and certain U.S. subsidiaries’ assets and initially provided $15 million in principal, with the facility permitting up to an additional $35 million of notes subject to conditions. Picard’s business centers on the SynCardia total artificial heart platform, and the filing details extensive business, regulatory, reimbursement, operational, and concentration risks that could materially affect its financial condition.
Picard Medical, Inc.17,000,000 shares of common stock for resale by HT Investments MA LLC and High Trail Special Situations LLC. These shares include up to 7,009,346 shares issuable upon exercise of warrants at an initial price of $2.675 per share and 9,990,654 shares issuable upon conversion, redemption or other settlement of senior secured notes due December 24, 2028.
Picard is a holding company whose operating subsidiary, SynCardia Systems, manufactures and sells the SynCardia total artificial heart, the only implantable total artificial heart approved in the United States and Canada as a bridge to heart transplantation for patients with biventricular heart failure. The company reports recurring net losses, including $21.1 million and $15.6 million for 2024 and 2023 and $22.7 million and $12.2 million for the nine months ended September 30, 2025 and 2024, with an accumulated deficit of $72.6 million as of September 30, 2025.
Picard will not receive proceeds from resale of the registered shares but may receive cash from any warrant exercises. An initial
Picard Medical, Inc. filed a current report describing a new communications initiative. The company issued a press release announcing the launch of the Cruxx to MedTech Podcast, a series that will explore the SynCardia Total Artificial Heart and the Emperor device. The press release is included as Exhibit 99.1 and is incorporated by reference. The company specifies that the information in this report and its exhibits is being furnished, not filed, so it is not subject to certain Exchange Act liability provisions or automatically incorporated into other securities filings.